A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Clinical trial NCT05720052 · TERMINATED

Trial details

NCT number: NCT05720052
Sponsor: MingSight Pharmaceuticals, Inc
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed or Refractory B-cell Lymphoma Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Marginal Zone Lymphoma (MZL)

Start date: 2023-02-06
Primary completion: 2023-11-28
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.